Phibro(PAHC)

Search documents
Here's What Key Metrics Tell Us About Phibro (PAHC) Q4 Earnings
ZACKS· 2024-08-29 00:00
Core Insights - Phibro Animal Health (PAHC) reported a revenue of $273.16 million for the quarter ended June 2024, marking a year-over-year increase of 7.1% and exceeding the Zacks Consensus Estimate by 4.09% [1] - The earnings per share (EPS) for the same period was $0.41, up from $0.38 a year ago, representing a surprise of 20.59% over the consensus estimate of $0.34 [1] Revenue Performance by Region - **Latin America and Canada**: Reported net sales of $70.17 million, exceeding the estimated $61.21 million, reflecting a year-over-year increase of 17.1% [3] - **Europe, Middle East and Africa**: Reported net sales of $32.41 million, slightly below the estimated $34.16 million, with a year-over-year change of 0.3% [4] - **United States**: Reported net sales of $153.68 million, surpassing the estimated $148.06 million, with a year-over-year increase of 5.9% [5] - **Asia Pacific**: Reported net sales of $16.91 million, below the estimated $19.02 million, representing a year-over-year decline of 5% [6] Segment Performance - **Animal Health**: Net sales reached $191.50 million, exceeding the estimated $182.82 million, with a year-over-year increase of 8.3% [7] - **Mineral Nutrition**: Reported net sales of $62.10 million, surpassing the estimated $60.62 million, reflecting a year-over-year increase of 6.3% [8] - **Animal Health - Vaccines**: Net sales of $32 million, exceeding the estimated $29.54 million, with a year-over-year increase of 14.3% [9] - **Animal Health - MFAs and other**: Reported net sales of $116.70 million, surpassing the estimated $107.92 million, reflecting a year-over-year increase of 12% [9] - **Animal Health - Nutritional specialties**: Reported net sales of $42.80 million, below the estimated $45.36 million, representing a year-over-year decline of 4% [10] - **Performance Products**: Reported net sales of $19.60 million, slightly above the estimated $19.01 million, with a year-over-year decline of 1.5% [11] Financial Metrics - **Adjusted EBITDA - Animal Health**: Reported at $41.30 million, exceeding the estimated $39.73 million [12] - **Adjusted EBITDA - Corporate**: Reported at -$16.30 million, worse than the estimated -$15.22 million [13] Stock Performance - Phibro's shares have returned +14.6% over the past month, outperforming the Zacks S&P 500 composite's +3.2% change, with a current Zacks Rank of 2 (Buy) indicating potential for further outperformance [13]
Phibro Animal Health (PAHC) Beats Q4 Earnings and Revenue Estimates
ZACKS· 2024-08-28 23:20
Phibro Animal Health (PAHC) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 20.59%. A quarter ago, it was expected that this maker of animal health products and nutritional supplements would post earnings of $0.29 per share when it actually produced earnings of $0.31, delivering a su ...
Phibro (PAHC) Stock Jumps 10.2%: Will It Continue to Soar?
ZACKS· 2024-08-26 10:31
Phibro Animal Health (PAHC) shares soared 10.2% in the last trading session to close at $20.94. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1% gain over the past four weeks. Phibro scored a strong price increase, on investors' optimism driven by its impending fiscal fourth-quarter 2024 financial results, which is slated to be released on Aug 28 post the closing bell. The Zacks Consensus Estimate for the fourth quarter revenue ...
Countdown to Phibro (PAHC) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
ZACKS· 2024-08-23 14:21
The upcoming report from Phibro Animal Health (PAHC) is expected to reveal quarterly earnings of $0.34 per share, indicating a decline of 10.5% compared to the year-ago period. Analysts forecast revenues of $262.44 million, representing an increase of 2.9% year over year. Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe. Prior to a comp ...
Phibro Animal Health (PAHC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ZACKS· 2024-08-21 15:06
Phibro Animal Health (PAHC) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on August 28, 2024, might help the stock move higher if these key numbers are better ...
Phibro (PAHC) Upgraded to Strong Buy: What Does It Mean for the Stock?
ZACKS· 2024-06-20 17:00
The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Most Powerful Force Impacting Stock Prices Harnessing the Power of Earnings Estimate Revisions Earnings Estimate Revisions for Phibro Bottom Line The upgrade of Phibro to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of ...
Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?
ZACKS· 2024-06-14 14:40
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. One company to watch right now is Phibro Animal Health (PAHC) . PAHC is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. The stock is trading with a P/E ratio of 12.62, which compares to its ind ...
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
zacks.com· 2024-05-29 14:46
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely o ...
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
Zacks Investment Research· 2024-05-13 14:46
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being un ...
Interpreting Phibro (PAHC) International Revenue Trends
Zacks Investment Research· 2024-05-13 13:51
Have you looked into how Phibro Animal Health (PAHC) performed internationally during the quarter ending March 2024? Considering the widespread global presence of this maker of animal health products and nutritional supplements, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall fin ...